Targeting the PI3K pathway with small molecular weight kinase inhibitors of PI3K, AKT, mTOR, HER2, or anti-HER2 antibodies has improved the outcome for many women with PI3K-activated breast cancer because the PI3K/mTOR pathway controls oncogenic processes such as tumor cell survival, motility, and invasion. This evidence concerns the gene AKT1 and neoplasm.